{"name":"Ariceum Therapeutics GmbH","slug":"ariceum-therapeutics-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNc0tHbjVTYVgtNEt1MF9VLTNoOEtxSDM0Z0FCd1dZaTlaZHVwakl1aV9sRnB6cXV4bVBLU3hieHAxTW9EeEYtTV9fTXlESDlCVkU5c3g4Y21nR1oxVTNwSTJMeDQ4UUN1bTgybEQwR0lCaGZEcHZ3WnpTNzZJQTlBbmwxTVhvdTlHWkZpQjRZNFJzcnRydlB4WTNzS1JERjhRU1JRSmNidmxnYVVQSDdDTko1R18tdnpQQ1NtVElOQTNsVG0xV0h0RkZ1MllOT0dzZEc3WU1rZGVfQTVoZ2hyQ3UzTFl0ek5MZDBVa2VDdDVkWkkxMDBrU0ZXaTBSRFdXcEo4b00xeHVQWHFncXliNkgtSzg4eEFmUzFIUWhzOF9KdTMtRl95Uw?oc=5","date":"2026-04-02","type":"pipeline","source":"GlobeNewswire","summary":"Radioligand Therapy Market Expected to Surge to $10.72 - GlobeNewswire","headline":"Radioligand Therapy Market Expected to Surge to $10.72","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOaUxDVmFjcmF4MmptQl9wMkJ4ZS1sQ0lVa0g4bEd3Smo0UkFyMnVhaXFzbkxvUHlJamZJd3dFejFIc3JtZTgxNlRJQ0Roc0VBSGVZNEt3S0ZOTklNMUl2V2dORWxCNnp4Xy1BTG1KekhDOThIbXFYblRpMXF1d1l2aW45QXktU2JSdGNaNTh4V2c5WDdncDk0bEc1OWxsQQ?oc=5","date":"2026-03-26","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Rapid Expansion in the Alpha Emitter Market - openPR.com","headline":"Emerging Growth Patterns Driving Rapid Expansion in the Alpha Emitter Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQbEN5WWhIR0psYXlsLTJONFJPeVJia1Y4X1h1eVdrbUVpdkJxTHVDWlRHcjNFOTkwcklLcGo4ZjBRSHZZSG90Z3llRVdXdFJUeDltUkFqc1Q0Z25IYkdsQk9ESEZ3MFF4YnFkaWR2MF9ILVg2QXcwYkx5NDg5RGhHN0ZPaXA4QnFTZkpOb3VzTy1qSkVXRjc4ek1rQUdvOW9RQjZOSF9JWjdTeUJVM2l3clJvTGt4NmxZQjRrdnZzZ2dMUkREcndlMW5MVzBiSXdFQk9tNm1TQXRMd05VT0JBRE5NVFI0bm5aQkpzX3R5MXNTMW5hd0R3N3ZLa3oxOVBxZ2pLbHpaU1oxTExEaE1tSzlNRW53aEtwbXJ1QUVMMlBSUV9xanRGa1hZSG8yRkJnYWc?oc=5","date":"2026-03-12","type":"pipeline","source":"PR Newswire","summary":"Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight - PR Newswire","headline":"Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQcjU5bDRhNEpsOXVYay1SWk13c012U2FKZHo4dS1aZW1pc2Rsc3NtbWFtbC1ZZW1hYzc4cWZhNzNPZTNvcTVkb2RaekpaaHM0OXZqOEl0c3ZtMkZUTVNGZVNubVNYSDlnS2t2YjNyQTJHa2NXS1NiTlFOblZETjRYbG5aTUh4S3R6NnVEcm5ZUDNHUkF6QnVLQjIxRGEwMVRhcS1v?oc=5","date":"2025-02-06","type":"pipeline","source":"BioWorld News","summary":"Ariceum’s [225Ac]satoreotide designated US orphan drug for SCLC - BioWorld News","headline":"Ariceum’s [225Ac]satoreotide designated US orphan drug for SCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOWRFS2FYRmtSZGplVzF3dG1kMV93bVZkN2lscjJHOXB6X1AxbXptbmp0a2FpUnlJMTJSOWVESkFObS1RWnB4NVdDMzlEWU5oS1I3MktUTWc5a1l1NER5STRfR3RsMENiLWYzVVJyTlFhY0pHdUxfX3BGb3dBb1dZcG9fYlJaNEo3elJOUHJXbE5CTzlhREtpeU1vSHAydDgzcnZfU1I3cXBCV2tFWHJSeEtWRTFjbmgzc0dVNHNyb1IxV2RJVXgyTFNrbmhLQnJXY0ktNzR4N1Jvcjhmek5wWnRhOXpIcWM?oc=5","date":"2025-01-15","type":"deal","source":"Citeline News & Insights","summary":"Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering - Citeline News & Insights","headline":"Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPSkJHUWFudnZieXJOb29PN3VIMExBRkl0eDcyaTFkWTBUMjZPZkdrbzdMV0ExbnZCeDYxb0p1QW9wLS10Um5wTFRXUTRlOUxVT0RXLW5YbG1PTUthMTNJMDFzbVpDVzJ3d3g2RzFpWnhJZm80djdLUjNhalk5VENmTm9mNnNHMjktVXg5MkFzSjNLUlIxRnBISVpoYmhpei1YMkRVVVN3Q0FFaXhXbGtCeGROLUY0cW5RWUNWRXp1cXRVRlY3MHZtdFN3?oc=5","date":"2024-06-21","type":"pipeline","source":"BioWorld News","summary":"SSO-110-based radiopharmaceuticals more efficacious against SST2 receptor-positive tumors - BioWorld News","headline":"SSO-110-based radiopharmaceuticals more efficacious against SST2 receptor-positive tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxObExlbUE0NFBWRk9YTm52bE9ucEg0RFhweDhlekFrX25TZmRETXphdmxYa2JXT21BbjB2RlVnQ3FDUWVCZDVtdlpHY1dBQkVTOFA2MXlmMHJwQTJOdVlRYmxXTjlHbDdRTVVQZ1ctOXQ3TWpQUTFOWHpHNXMxYm54dHhYVWY3WHRZZlJvUEJMd2V3RllPWldiZURjTDVGeEJF?oc=5","date":"2024-02-14","type":"pipeline","source":"Fierce Biotech","summary":"Earlybird gets the €173M worm, building nest egg for European healthcare companies - Fierce Biotech","headline":"Earlybird gets the €173M worm, building nest egg for European healthcare companies","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}